104 Non-Hodgkin Lymphoma

Question 1

This specific subtype of NHL has a striking geographic occurrence, being most frequent in South Asia and parts of Latin America (H20 C104 P770)

Answer 1

Angiocentric nasal T/NK cell lymphoma

Question 2

Lymphoid malignancy associated with HTLV-1 infection (H20 C104 P771)

Answer 2

Adult T cell leukemia/lymphoma

Question 3

Lymphoid malignancy associated with HCV infection (H20 C104 P771)

Answer 3

Lymphoplasmacytic lymphoma

Question 4

Infectious agent associated with Burkitt lymphoma, post–organ transplant lymphoma, primary CNS diffuse large B-cell lymphoma, Hodgkin lymphoma, and nasal type extranodal NK/T-cell lymphoma (H20 C104 P771)

Answer 4

Epstein-Barr virus

Question 5

Infectious agent associated with diffuse large B-cell lymphoma and Burkitt lymphoma (H20 C104 P771)

Answer 5

HIV

Question 6

Infectious agent associated with gastric MALT lymphoma (H20 C104 P771)

Answer 6

Helicobacter pylori

Question 7

Infectious agent associated with MALT lymphoma of the skin (H20 C104 P771)

Answer 7

Borrelia sp.

Question 8

Infectious agent associated with MALT lymphoma of the conjunctiva (H20 C104 P777)

Answer 8

Chlamydophila psittaci

Question 9

Infectious agent associated with small intestine MALT lymphoma (H20 C104 P771)

Answer 9

Campylobacter jejuni

Question 10

Infectious agent associated with primary effusion lymphoma and multicentric Castleman disease (H20 C104 P771)

Answer 10

Human herpesvirus 8

Question 11

Type of NHL that is most frequently associated with immunosuppresion and autoimmune disease (H20 C104 P771)

Answer 11

DLBCLs

Question 12

The master B lineage transciption factor (H20 C104 P771)

Answer 12

PAX5

Question 13

T-cell master regulatory transciption factor (H20 C104 P771)

Answer 13

NOTCH-1

Question 14

Imaging test of choice in assessing lymphadenopathy for aggressive lymphomas (H20 C104 P773)

Answer 14

FDG PET

Question 15

End-of-treatment FDG PET should preferably be done how many weeks after chemotherapy (H20 C104 P773)

Answer 15

6-8 weeks

Question 16

End-of-treatment FDG PET should preferably be done how many weeks after radiation or radiochemotherapy (H20 C104 P773)

Answer 16

8-12 weeks

Question 17

Best predictor of outcome for NHL (H20 C104 P774)

Answer 17

International Prognostic Index

Question 18

Independent prognostic variable that is included in follicular lymphoma prognostic index but is not included in the IPI (H20 C104 P774)

Answer 18

Hemoglobin <12

Question 19

Second most common NHL and most common indolent NHL (H20 C104 P774)

Answer 19

Follicular lymphoma

Question 20

All of the intensive combination chemotherapy regimens for Burkitt’s lymphoma involve this drug (H20 C104 P775)

Answer 20

Cyclophosphamide

Question 21

Most common histologic subtype of NHL (H20 C104 P775)

Answer 21

Diffuse large B-cell lymphoma

Question 22

Standard first-line chemotherapy for DLBCL (H20 C104 P775)

Answer 22

R-CHOP

Question 23

New agent for relapsed DLBCL, particularly in the ABC cell of origin (H20 C104 P776)

Answer 23

Ibrutinib

Question 24

Treatment for relapsed/refractory DLBCL following two prior systemic therapies (H20 C104 P776)

Answer 24

Anti-CD19 CAR-T cells

Question 25

>85% of patients with FL will harbor t(14;18) and overexpress this protein: (H20 C104 P776)

Answer 25

BCL2

Question 26

No. of centroblasts in grade II FL (H20 C104 P776)

Answer 26

6-15 centroblasts/hpf

Question 27

This grade of FL is an aggressive disease and is treated like DLBCL (H20 C104 P776-7)

Answer 27

Grade IIIb FL

Question 28

Best predictor of outcome in FL (H20 C104 P776)

Answer 28

FLIPI

Question 29

Standard of care for the first line therapy of medium to high volume follicular lymphoma (H20 C104 P777)

Answer 29

Bendamustine + Rituximab (BR)

Question 30

This treatment for FL is associated with considerable treatment-related morbidity so is usually reserved for patients with multiply relapsed FL that is no longer responsive to chemotherapy. (H20 C104 P777)

Answer 30

Allogeneic HSCT

Question 31

Rate of transformation of FL to DLBCL (H20 C104 P777)

Answer 31

~3% per year

Question 32

Aside from rituximab, this treatment for splenic MZL is reasonable for selected patients with excellent relief of symptoms and cytopenias (H20 C104 P777)

Answer 32

Splenectomy

Question 33

Most common cytogenetic abnormality in MALT lymphoma (H20 C104 P777)

Answer 33

t(14;18)

Question 34

Lymphoplasmacytic lymphoma with high levels of circulating IgM paraproteins (H20 C104 P777)

Answer 34

Waldenstrom macrogobulinemia

Question 35

Variant of mantle cell lymphoma that is more indolent (H20 C104 P778)

Answer 35

SOX11 variant

Question 36

Variant of mantle cell lymphoma that is associated with a poor prognosis (H20 C104 P778)

Answer 36

Blastic variant

Question 37

Pathognomonic cytogenetic findings in mantle cell lymphoma (H20 C104 P778)

Answer 37

t(11;14)

Question 38

Mycoisi fungoides associated with generalized erythroderma and circulating tumor cells (H20 C104 P778)

Answer 38

Sézary syndrome

Question 39

Histologic finding in anaplastic large cell lymphoma (H20 C104 P779)

Answer 39

Hallmark cells

Question 40

Conjugated anti-CD30 antibody to monomethly aurostatin E used to treat ALCL patients with chemosensitive disease or for ALK-negative disease (H20 C104 P779)

Answer 40

Brentuximab

Question 41

This type of lymphoma can be prevented with a gluten-free diet (H20 C104 P779)

Answer 41

Type I enteropathy-type intestinal T-cell lymphoma

Question 42

Adult T-cell leukemia/lymphoma is more prevalent in these regions [2] of the world (H20 C104 P779)

Answer 42

Japan, Caribbean basin

Question 43

Most common vairant of ATLL (H20 C104 P779)

Answer 43

Acute variant

Question 44

Pathognomonic histologic finding in adult T-cell leukemia/lymphoma (H20 C104 P779)

Answer 44

Flower cell